In vitro tests for predicting drug-drug interactions:: The need for validated procedures

被引:26
作者
Kremers, P [1 ]
机构
[1] CHU, Adv Technol Corp, Inst Pathol, B-4000 Sart Tilman Par Liege, Belgium
来源
PHARMACOLOGY & TOXICOLOGY | 2002年 / 91卷 / 05期
关键词
D O I
10.1034/j.1600-0773.2002.910501.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Over the past decade, the prediction of drug-drug interactions from in vitro studies has become a rapidly expanding field of research. Numerous papers and excellent review articles (Bertz Granneman 1997; Ito et aL 1998a b; Lin 2000; Bachmann Ghosh 2001; Ekins Wrighton 2001; Weaver 2001) have been published in this area. Yet like any new and fast-growing subject, this one has been developing with some confusion and without any real, efficient organisation. Depending on the drug tested, the models and extrapolation parameters used, etc., results and conclusions may vary widely from study to study (von Moltke et al. 1998; Weaver 2001). Several authors have called for validation of these procedures (Rodrigues et al. 2001; Kummar & Surapaneni 2001; Pelkonen et al. 2001a b; Kremers 2002), and regulatory authorities intend to require better traceability and reliability (FDA & EMEA guidelines). A systematic and reliable approach is needed also to allow such protocols to be incorporated into early screening for potential drugs and new chemical entities. There is certainly a great need to standardise these studies and to verify their conclusions, but is true validation possible in this field? The main purpose of the present paper is to discuss this issue and to examine what is possible and what is needed to improve the quality of predictions made from in vitro experiments.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 59 条
[1]  
[Anonymous], 2001, BIOAN METH VAL GUID
[2]   The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions [J].
Bachmann, KA ;
Ghosh, R .
CURRENT DRUG METABOLISM, 2001, 2 (03) :299-314
[3]  
Balls M, 1995, ATLA-ALTERN LAB ANIM, V23, P884
[4]  
BALLS M, 1995, ATLA-ALTERN LAB ANIM, V23, P129
[5]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[6]  
BLAAUBOER BJ, 1994, ATLA-ALTERN LAB ANIM, V22, P231
[7]  
BOOBIS A, 2002, IN PRESS EUR J PHARM
[8]   Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples [J].
Boobis, AR ;
McKillop, D ;
Robinson, DT ;
Adams, DA ;
McCormick, DJ .
XENOBIOTICA, 1998, 28 (05) :493-506
[9]   The use of long-term hepatocyte cultures for detecting induction of drug metabolising enzymes: The current status - ECVAM hepatocytes and metabolically competent systems task force report 1 [J].
Coecke, S ;
Rogiers, V ;
Bayliss, M ;
Castell, J ;
Doehmer, J ;
Fabre, G ;
Fry, J ;
Kern, A ;
Westmoreland, C .
ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 1999, 27 (04) :579-638
[10]   The principles of good laboratory practice:: Application to in vitro toxicology studies -: The report and recommendations of ECVAM Workshop 37 [J].
Cooper-Hannan, R ;
Harbell, JW ;
Coecke, S ;
Balls, M ;
Bowe, G ;
Cervinka, M ;
Clothier, R ;
Hermann, F ;
Klahm, LK ;
de Lange, J ;
Liebsch, M ;
Vanparys, P .
ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 1999, 27 (04) :539-577